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TRAF2 or TRAF6, and therefore may function as a domi-1Division of Immunology
nant-negative form of TRAF1 (Carpentier and Beyaert,2 Howard Hughes Medical Institute
1999; Irmler et al., 2000; Leo et al., 2000). In contrast,Children’s Hospital and Department of Pediatrics
TNF-induced activation of c-Jun N-terminal kinase (JNK)Harvard Medical School
is prolonged in transfectants overexpressing TRAF1,Boston, Massachusetts 02115
whereas overexpression of a TRAF1 mutant in which
the N-terminal part was replaced by green fluorescent
protein interferes with TNF-induced activation of NF-BSummary
and JNK (Schwenzer et al., 1999). TRAF1, TRAF2, and
the cellular inhibitor-of-apoptosis proteins were identi-TNF receptor-associated factor 1 (TRAF1) is a unique
fied as gene targets of NF-B-dependent transcriptionalTRAF protein because it lacks a RING finger domain
activity (Wang et al., 1998). In studies using TRAF1 trans-and is predominantly expressed in activated lympho-
genic mice, TRAF1 was shown to play an inhibitory rolecytes. To elucidate the function of TRAF1, we gener-
in antigen-induced apoptosis of CD8 T lymphocytesated TRAF1-deficient mice. TRAF1/ mice are viable
(Speiser et al., 1997).and have normal lymphocyte development. TRAF1/
To gain further insight into TRAF1 function, we haveT cells exhibit stronger than wild-type (WT) T cell prolif-
generated TRAF1 null (TRAF1/) mice. Althougheration to anti-CD3 mAb, which persisted in the pres-
TRAF1/ mice have normal lymphocyte development,ence of IL-2 or anti-CD28 antibodies. Activated
T cells from these mice exhibit increased proliferationTRAF1/ T cells, but not TRAF1/ T cells, responded
to anti-CD3 stimulation compared with WT T cells. Moreto TNF by proliferation and activation of the NF-B
importantly, anti-CD3 activated T cells from TRAF1/and AP-1 signaling pathways. This TNF effect was me-
mice, but not from WT controls, responded to TNF bydiated by TNFR2 (p75) but not by TNFR1 (p55). Further-
proliferation and activation of the NF-B and AP-1 sig-more, skin from TRAF1/ mice was hypersensitive to
naling pathways. Furthermore, skin from TRAF1/ miceTNF-induced necrosis. These findings suggest that
is hypersensitive to lymphocyte-dependent TNF-inducedTRAF1 is a negative regulator of TNF signaling.
skin necrosis. Taken together, these findings indicate
that TRAF1 is a negative regulator of TNF signaling inIntroduction
T lymphocytes.
TRAF1 and TRAF2 were originally discovered due to
Resultstheir ability to bind to TNFR2 (Rothe et al., 1994). Six
TRAFs have been described to date (Arch et al., 1998).
Generation of TRAF1-Deficient MiceMembers of the TNF receptor superfamily, including
To elucidate the function of TRAF1 in vivo, we disruptedTNFR2, CD27, CD30, and CD40, may associate with one
the murine traf1 gene by gene targeting. A portion ofor several TRAFs (Arch et al., 1998). TRAF2, TRAF3,
the murine traf1 gene and the targeting construct areTRAF5, and TRAF6 were shown to be important for the
shown in Figure 1A. Exons 2 to 5, including the firstactivation of both NF-B and AP-1 transcription factors
coding exon (exon 4), were replaced by the neomycin
by members of TNFR family. In general, TRAF molecules
resistance gene following homologous recombination
are characterized by the presence of an N-terminal RING
in embryonic stem cells. Genomic DNA from individual
finger, several zinc fingers, and a C-terminal TRAF do- neoresistant ES clones was prepared, digested with
main, which is important for interactions with receptors EcoRI, and used for Southern blotting analysis with a
and other TRAF proteins. TRAF1 is a unique member of 3 probe (Figure 1A). ES clones with targeted disruption
the TRAF family; it contains a single zinc finger and a of one of the traf1 alleles were identified by the presence
TRAF domain. Its expression is restricted to spleen, of the novel 10 kb fragment derived from the targeted
lung, and testis, in contrast to the more ubiquitous ex- allele in addition to the 12 kb fragment derived from the
pression of other TRAFs (Mosialos et al., 1995; Rothe WT allele (Figure 1B). Of 38 analyzed ES clones, three
et al., 1994). TRAF1 can be recruited to a number of were identified to contain a disrupted allele. TRAF1/
distinct members of the TNFR superfamily, including mice were derived by standard techniques and identified
TNFR2, CD27 (Yamamoto et al., 1998), CD30 (Tsitsikov by PCR and/or Southern blotting of tail DNA, as de-
et al., 1997), 4-1BB (Jang et al., 1998; Saoulli et al., 1998), scribed in Experimental Procedures. Western blotting
OX-40 (Kawamata et al., 1998), HVEM/ATAR (Marsters analysis with polyclonal antibody against a C-terminal
et al., 1997), TRANCE-R (Wong et al., 1998), XEDAR TRAF1 peptide revealed that CD40-stimulated spleno-
(Yan et al., 2000), and also to Epstein-Barr virus latent cytes from TRAF1/ mice have no detectable TRAF1
infection membrane protein 1 (Mosialos et al., 1995). expression (Figure 1D). TRAF1/ mice were raised in
Little is known about the biochemical function of a germ-free environment and did not display apparent
differences from WT littermates in growth, weight, or
health.3 Correspondence: tsitsikov_e@hub.tch.harvard.edu
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Figure 1. Generation of TRAF1-Deficient Mice
(A) Partial structure of the murine TRAF1 gene (above) and of the targeting construct (below). Exons are represented by bold segments.
Neomycin resistance (neo) and thymidine kinase (TK) genes are indicated. PCR primers are represented by small arrows.
(B) Southern blot analysis of DNA from ES cell clones. Genomic DNA was digested by EcoRI and probed with the HindIII/EcoRI fragment
shown in (A). The wild-type allele is represented by the 12 kb band, whereas the knockout allele is represented by the 10 kb band.
(C) Western blot analysis of TRAF1 expression in 50  106 splenocytes from wild-type (WT) and TRAF1-deficient (KO) mice. Cells were
stimulated with anti-CD40 antibodies overnight, lysed, and TRAF1 expression was evaluated with polyclonal anti-TRAF1 antibodies.
Normal Development of T and B Lymphocytes TRAF2, TRAF3, TRAF5, and TRAF6 knockout (KO)
mice have impaired antibody responses to T-dependentin TRAF1/ Mice
TRAF1/ mice have thymi of normal size and architec- antigens (Lomaga et al., 1999; Nakano et al., 1999; Nguyen
et al., 1999; Xu et al., 1996). To determine the role ofture. Detailed FACS analysis revealed no difference in
the numbers of CD4, CD8, TCR, TCR	, CD2, and TRAF1 protein in antibody immune responses, we im-
munized TRAF1/ mice and WT littermates with theCD3 positive thymocytes between WT and TRAF1/
mice (data not shown). Bone marrow from TRAF1/ T-dependent antigen ovalbumin. Figure 2 shows that
TRAF1/ mice have normal IgG1, IgG2a, and IgE anti-mice has normal numbers of IgM B cells with normal
expression of CD43 and B220 (data not shown). Taken ovalbumin responses (Figures 2B–2D), suggesting intact
T cell help and intact immunoglobulin isotype switchingtogether, these results indicate that TRAF1 expression
is not necessary for T or B lymphocyte development. in B cells. The antibody responses of TRAF1/ mice to
the type 1 T-independent antigen TNP-LPS and to theSpleens from TRAF1/ mice are of normal size and
have normal T and B cell numbers; normal expression type 2 T-independent antigen TNP-Ficoll (Figures 2E
and 2F) were also normal. These results suggest thatof the B cell surface markers B220, sIgM, sIgD, CD5,
CD21, CD23, CD40, and HSA; and normal expression antigen specific antibody responses are not dependent
on TRAF1.of the T cell surface markers CD4, CD8, TCR, TCR	,
CD2, and CD3 molecules (data not shown).
Analysis of inguinal lymph nodes revealed a significant Enhanced Proliferation of TRAF1/
T Cells to Anti-CD3 mAbincrease in the number of total lymphocytes in TRAF1/
mice (2.74 
 0.37 106 in TRAF1/ mice versus 1.09
 To determine whether TRAF1 is important for T cell pro-
liferation, the in vitro responses of TRAF1/ T cells to0.32  106 in WT littermates, p  0.05), as well as an
increased T/B cell ratio, but a normal CD4/CD8 ratio ligation of the TCR/CD3 complex was compared with
that of T cells from WT littermates. Purified spleen T(data not shown).
cells from TRAF1/ mice exhibited higher proliferation
to immobilized anti-CD3 mAb than WT T cells (FigureNormal B Cell Proliferation and Antibody Responses
in TRAF1-Deficient Mice 3A). The increased T cell proliferation in response to
anti-CD3 mAb was not due to impaired activation-Stimulation through the IgM B cell receptor or CD40
induces TRAF1 expression in B cells (Dunn et al., 1999; induced cell death because the fraction of annexin V
staining T cells following anti-CD3 activation was similarZapata et al., 2000). Furthermore, TRAF1 has been re-
ported to be associated with CD40 (Pullen et al., 1998). in TRAF1/ and WT mice (Figure 3B).
Interactions between IL-2 and its receptor play anWe therefore examined the proliferative response of B
cells from TRAF1/ mice to IgM or CD40 ligation. Figure important role in T cell proliferation, and optimal produc-
tion of IL-2 by T cells requires costimulation via CD282A shows that B cells from TRAF1/ mice have normal
proliferation to anti-IgM or anti-CD40 antibodies. Fur- (Sharpe, 1995). IL-2R (CD25) chain expression follow-
ing anti-CD3 stimulation was comparable in TRAF1/thermore, electrophoretic mobility shift assay (EMSA)
analysis revealed normal activation of the transcrip- and WT T cells (Figure 3C). Furthermore, intracellular
IL-2 protein content as assessed by FACS was equiva-tion factors NF-B and AP-1 following CD40 ligation in
TRAF1/ B cells (data not shown). lent in TRAF1/ and WT T cells (Figure 3D). Significantly
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Figure 2. B Cell Proliferation and Antibody
Responses in TRAF1-Deficient Mice
(A) Proliferation of wild-type (closed bars) and
TRAF1/ (striped bars) B lymphocytes to
anti-IgM and anti-CD40 stimulation. For pro-
liferation, purified spleen B cells were cul-
tured and activated by F (ab)2 fragments of
polyclonal anti-IgM antibodies or anti-CD40
mAb HM40-3 for 72 hr at 1  105/well. [3H]-
thymidine was added (1 Ci /well) during the
last 6 hr of culture. Values represent mean 

SE.
(B–D) Response to the T-dependent antigen
ovalbumin. Wild-type (open circles) and
TRAF1/ (closed circles) littermate mice
were intravenously immunized with 20 g
ovalbumin/alum at day 0 and boosted with
the same dose at day 21. Ovalbumin-specific
IgG1 (B), IgG2a (C), and IgE (D) were mea-
sured at day 28. Isotype-specific mAbs were
absorbed to 96-well plates. Sera were diluted
(1/1000 for IgG1, 1/50 for IgG2a, and 1/25 for
IgE,) and added to the wells. Next, biotinyl-
ated-ovalbumin was added to the wells and
revealed with the strepavidin-peroxidase
conjugate.
(E) Response to type 1 T-independent antigen
TNP-LPS. Mice were immunized intraperito-
neally with 10 g TNP-LPS in PBS at day 0.
(F) Response to the type 2 T-independent an-
tigen TNP-Ficoll. Mice were immunized intra-
peritoneally with 10 g TNP-Ficoll in PBS at
day 0. Sera were diluted 1/1000 and levels of
antigen-specific antibody responses of the
indicated isotypes were analyzed by TNP-
specific ELISA. Mean values
 SEM obtained
for at least four mice per group are shown.
higher proliferation of TRAF1/ T cells persisted when and 4C). Also, as expected, small compensatory
changes could be detected in the V6CD4 andT cells were stimulated with submitogenic concentra-
tions of anti-CD3 mAb and increasing concentrations of V6CD8 subsets, which are not engaged by SEB (Fig-
ures 4B and 4D). Following injection of SEB, TRAF1/anti-CD28 mAb or of recombinant IL-2 (Figures 3E and
3F). These results suggest that pathways other than mice displayed changes in the V8 and V6 subsets
identical to those of WT mice.the IL-2 pathway may be responsible for the enhanced
proliferation of TRAF1/ T cells to TCR ligation. We also assessed in vivo proliferation of T cells by
the extent of BrdU incorporation. Neither CD4nor CD8
V8-bearing proliferating T cells showed detectable dif-Superantigen-Induced Clonal Expansion and Deletion
ferences between WT and TRAF1/ mice (data notIs Normal in TRAF1-Deficient Mice
shown). Apoptosis in the CD4 and CD8 populationsThe enhanced proliferation of T cells from TRAF1/
was estimated by surface staining with annexin V-FITC.mice in response to TCR ligation in vitro prompted us
No detectable differences in activation dependent cellto evaluate the role of TRAF1 in T cell proliferation and
death in response to SEB injection were observed be-apoptosis in vivo in a superantigen-induced clonal
tween WT and TRAF1/ T cell populations (data notexpansion/deletion model (Kawabe and Ochi, 1991;
shown).MacDonald et al., 1991; Wahl et al., 1993). In mice, the
bacterial superantigen staphylococcal enterotoxin B
(SEB) is recognized by T cells bearing V8.1 or V8.2 TNF-Mediated Signaling Is Enhanced
in TRAF1/ T LymphocytesT cell receptors. SEB injection causes first an early (day
1) decrease in V8peripheral T cells. This is followed by A possible pathway that may underlie the hyperrespon-
siveness of TRAF1/ T cells to CD3 stimulation maytransient proliferative expansion of V8 T cells, which
peaks on day 2. Finally, there is deletion of the V8 involve TNFR family members, which are known to asso-
ciate with TRAF1 and to be expressed on T cells. TheseT cell subset by apoptosis (days 5–30). We injected WT
and TRAF1/ mice with 20 g of SEB and analyzed include CD27 (Hintzen et al., 1995), CD30 (Horie and
Watanabe, 1998), 4-1BB (Hurtado et al., 1995), OX-40changes of V8 CD4 and CD8 T cell populations in
the lymph nodes. As expected, all three phases of (Gramaglia et al., 1998), HVEM/ATAR (Tamada et al.,
2000), AITR (Kwon et al., 1999), and TNFR2 (Cope et al.,the response were observed in both V8CD4 and
V8CD8 subsets of T cells in WT mice (Figures 4A 1995; Zheng et al., 1995). Addition of TNF had no effect
Immunity
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Figure 3. Response of TRAF1-Deficient T Lymphocytes in Response to Anti-CD3 Stimulation
(A) Proliferation of T cells from wild-type (open circles) and TRAF1/ (closed circles) littermate mice in response to anti-CD3 mAb. Purified
spleen T cells were cultured for 72 hr at 1  105/well in plates coated with different concentrations of immobilized anti-CD3 mAb 145-2C11.
[3H]-thymidine was added (1 Ci /well) during the last 6 hr of culture. Values represent mean 
 SE.
(B–D) FACS analysis of wild-type (WT) and TRAF1/ (KO) T cells in response to immobilized anti-CD3 mAb (1 g/ml). After 24 hr of activation,
T cells were stained for the binding of Annexin V (B), the expression of CD25 (IL-2R) (C), and synthesis of intracellular IL-2 (D). The dotted
line indicates cells stained with isotype control antibodies, and the solid line indicates cells stained with anti-CD25 or anti-IL-2 antibodies.
Each experiment shown is representative of experiments performed on at least four pairs of mice.
(E and F) T cells were also examined for proliferation to immobilized anti-CD3 mAb (coating concentration of 0.1 g/ml) in the presence of
immobilized anti-CD28 37.51 mAb at the indicated coating concentrations (E) or increasing concentrations of recombinant IL-2 (F).
on the proliferation of WT or TRAF1/ freshly isolated Enhanced TNF-Dependent Activation
of TRAF1/ CellsT cells in response to anti-CD3 mAb (data not shown).
This was not surprising, because resting T cells express TNFR2 engagement leads to the activation of the NF-
B and AP-1 transcription factors, which play importantlow or no detectable amounts of either TNFR2 or TRAF1
(Dunn et al., 1999; Scheurich et al., 1987). In contrast, roles in TNF-mediated cell activation (Aggarwal et al.,
1999). We examined the IB kinase (IKK) activity in anti-WT and TRAF1/ T cells that were preactivated with
immobilized anti-CD3 mAb for 3 days expressed similar CD3 activated T cells by phosphorylation of a GST-
IB(1-66) fusion protein after TNF stimulation. Figureamounts of TNFR2 but no detectable TNFR1 (Figure 5A),
in agreement with a previous report describing TNFR2 6A shows that GST-IB(1-66) was phosphorylated by
lysates from TNF-treated TRAF1/ T cells (lanes 5–8)as the principal TNF receptor on activated T cells (Zheng
et al., 1995). Figure 5B shows that addition of TNF had but not by lysates of TNF-treated WT T cells (lanes 2–4).
This phosphorylation was specific to the IB serine resi-little effect on the proliferation of activated WT T cells
but significantly enhanced the proliferation of activated dues, because a GST-IB(AA) mutant was not phosphor-
ylated in TRAF1/ T cells.TRAF1/ T cells. To determine which of the two known
TNFRs mediates the proliferative response of activated NF-B binding activity was measured by EMSA in
nuclear extracts prepared from anti-CD3 preactivatedTRAF1/ T cells to TNF, we examined the capacity of
TNFR1 and TNFR2 specific mAbs to block the effect of WT and TRAF1/ T cells treated with TNF. Figure 6B
shows that TNF caused enhanced activation of NF-BTNF. Figure 5C shows that anti-TNFR2 mAb TR75-54,
but not anti-TNFR1 mAb 55R170, blocked proliferation in TRAF1/ T cells (lane 5). In contrast, TNF caused no
detectable increase of NF-B activation in WT T cellsof activated TRAF1/ T cells to TNF. These results sug-
gest that in WT T cells, TRAF1 negatively regulates pro- (lane 2). Treatment with PMA caused comparable activa-
tion of NF-B in WT (lane 3) and TRAF1/ (lane 6) T cells,liferative signals delivered via TNFR2 to activated T cells.
TRAF1 Is a Negative Regulator of TNF Signaling
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Figure 4. Clonal Deletion and Expansion of Peripheral V8-Bearing
T Cells in SEB-Injected TRAF1-Deficient Mice
On day 0, wild-type (closed circles) and TRAF1/ (open circles)
mice received a single intraperitoneal injection of SEB (20 g). On
days 0, 1, 2, 5, and 8, percentage of lymph node CD4V8 (A),
CD4V6 (B), CD8V8 (C), or CD8V6 (D) cells was determined
by FACS analysis. Each point represents the mean 
 SE for six
mice from two separate experiments.
indicating that there is no difference in the intrinsic in-
duction of NF-B in TRAF1/ T cells. Figure 6C shows
that TNF induced the NF-B-dependent transcription of
Figure 5. TRAF1-Deficient T Cells Proliferate in Response to TNFIB and A20 mRNAs in anti-CD3 activated TRAF1/ but
(A) Expression of TNF receptors on activated wild-type (WT) andnot in WT T cells.
TRAF1/ (KO) T cells. Purified spleen T cells were prestimulatedTNF induces phosphorylation and activation of the
with anti-CD3 mAb (1 g/ml) for 72 hr and stained with biotinylatedstress-activated protein kinase/JNK (SAPK/JNK), which
isotype control (dotted line), anti-TNFR1 (dashed line), and anti-
is critical for activation of the transcription factor AP-1. TNFR2 (solid line) mAbs. Binding of biotinylated antibodies was
Figure 6D shows that TNF induced the JNK phosphory- revealed by Streptavidin-PE.
lation in activated TRAF1/ cells but not in WT cells. (B) Proliferation of activated wild-type (open circles) and TRAF1/
(closed circles) T cells in response to stimulation with TNF. LiveWe also examined AP-1 binding activity in these cells.
activated T cells as described in (A) were cultured at 2  104/wellFigure 6E shows that TNF caused enhanced activation
for an additional 72 hr with indicated concentrations of recombinantof AP-1 in TRAF1/ T cells (lane 5) but not in WT T cells
TNF and pulsed with [3H]-thymidine (1 Ci /well) for the last 6 hr of
(lane 2), although both types of cells activated AP-1 culture.
comparably in response to PMA. Taken together, these (C) Effect of anti-TNF receptors antibodies on proliferation of acti-
findings suggest that TRAF1 inhibits TNFR2-mediated vated wild-type (open bars) and TRAF1/ (closed bars) T cells. T
cells were activated and stimulated with 100 ng/ml of TNF. Blockingactivation of NF-B and AP-1in T cells.
anti-TNFR1 (55R-170) and anti-TNFR2 (TR75-54) mAbs (2 g/ml)
were added separately or together to T cells 30 min before theTNF-Induced Skin Necrosis Is Exaggerated
addition of TNF (50 ng/ml). Data represent the mean values within
in TRAF1-Deficient Mice an experiment with error bars representing the SE of the mean.
We sought an in vivo model for enhanced respon- Every experiment was repeated with at least four pairs of mice.
siveness to TNF. Injection of TNF into mouse skin causes
necrosis, which is dependent on both TNFR1 and TNFR2
(Amar et al., 1995; Erickson et al., 1994; Sheehan et al., with injection of 0.4 g of TNF in either type of mouse
(data not shown).1995). Injection of 3 g of TNF for 5 days caused skin
necrosis to a similar degree in TRAF1/ and WT mice Histologic examination revealed no differences be-
tween uninjected skin from normal and TRAF1/ mice(Figure 7A) but failed to induce detectable skin necrosis
in RAG-2/ mice, suggesting that TNF skin necrosis is (Figure 7B). Biopsies from skin of WT and TRAF1/
mice injected with 3.0 g of TNF revealed an almostdependent on lymphocytes. Injection of a suboptimal
amount (1.5 g) of TNF produced barely visible hemor- complete loss of the epidermis and extensive cellular
damage in the dermis and hypodermis, including vacuo-rhages in the skin of WT mice. In contrast, the same
dose caused macroscopic ulceration and skin necrosis lization and disintegration. Identical changes were ob-
served in skin of TRAF1/ mice injected with 1.5 g ofin TRAF1/ mice. There were no visible skin changes
Immunity
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the expression of TRAF1 being restricted mostly to
lymphoid cells. TRAF5-deficient mice, like TRAF1-defi-
cient mice, survive normally (Nakano et al., 1999). In
contrast, TRAF2- and TRAF3-deficient mice exhibit lym-
phopenia and die prematurely (Xu et al., 1996; Yeh et
al., 1997), and TRAF4-deficient mice exhibit tracheal
malformations (Shiels et al., 2000). TRAF6-deficient mice
display severe osteopetrosis, become runted, and die
at the age of 17–19 days (Lomaga et al., 1999; Naito et
al., 1999).
Although the T and B phenotype of lymphoid organs
from TRAF1 mice (data not shown) and the function
of TRAF1/ B cells (Figure 2) appeared to be normal,
TRAF1/ T cells displayed exaggerated proliferation in
response to stimulation by anti-CD3 (Figure 3). This was
not accompanied by increased apoptosis, enhanced
IL-2R (CD25) expression, or increased IL-2 production,
and it persisted in the presence of costimulation with
anti-CD28 antibodies and upon addition of IL-2. These
results suggest that TRAF1 normally inhibits TCR/CD3-
mediated activation by interfering with signaling path-
ways different from CD28 or IL-2. Candidate pathways
may include those initiated by the TRAF1-associated
TNFR family members, including TNFR2, CD30, OX40,Figure 6. Activated TRAF1-Deficient T Cells Are Hyperresponsive
to TNF CD27, 4-1BB, HVEM/ATAR, and AITR. Signaling through
Signaling by activated wild-type (WT) and TRAF1/ (KO) T cells some of them was shown to enhance T cell proliferation
was stimulated with TNF (400 ng/ml) for indicated time points. to anti-CD3 stimulation (Akiba et al., 1998; Gramaglia et
(A) Phosphorylation of GST-IB in vitro. Whole-cell lysates were al., 2000; Hintzen et al., 1995; Hurtado et al., 1997). More
prepared, and then in vitro kinase assays were performed with GST- importantly, T cells from OX40/ and CD27/ mice
IB (1-66) and GST-IB(AA) fusion proteins.
proliferate poorly in response to anti-CD3 stimulation(B) EMSA with NF-B oligonucleotide probe and nuclear extracts
(Hendriks et al., 2000; Kopf et al., 1999; Pippig et al.,from T cells, which were left unstimulated or stimulated with TNF
1999). Therefore, loss of TRAF1 may amplify the costim-or PMA for 30 min.
(C) Northern blotting analyses of IB, A20, and L32 mRNA ex- ulatory signal delivered by these molecules, resulting in
pression. increased responsiveness to anti-CD3 activation. Future
(D) Phosphorylation of SAPK/JNK. After stimulation, T cells were experiments will test this hypothesis.
lysed, and phophorylation of SAPK/JNK was determined with anti-
TNF caused marked proliferation of preactivated Tphospho-SAPK antibody by Western blotting analysis. Equal loading
cells from TRAF1/ mice (Figure 5). In contrast, itwas ascertained with anti-phospho-SAPK antibody. Two p46 and
caused no detectable proliferation of preactivated WTp54 isoforms of SAPK/JNK are indicated.
(E) EMSA with AP-1 oligonucleotide probe and nuclear extracts from T cells. In agreement with the selective expression of
T cells, which were left unstimulated or stimulated with TNF or PMA TNFR2, but not TNFR1, on activated T cells, the re-
for 30 min. sponse of TRAF1/ T cells to TNF was completely abro-
gated by antagonistic antibodies to TNFR2 but not by
antagonistic antibodies to TNFR1, indicating that TRAF1
TNF. In contrast, skin of WT mice injected with 1.5 g inhibits activation signals delivered via TNFR2. The role
of TNF displayed markedly less damage to the epidermis of TNF in the enhanced proliferation of TRAF1/ T cells
and markedly less hemorrhage and tissue disintegration to anti-CD3 will be examined by studying mice double
in the dermis and hypodermis but displayed intense deficient for TRAF1 and TNF.
infiltration by lymphocytes, neutrophils, and macro- The transcription factors NF-B and AP-1 are acti-
phages. Taken together, these results indicate that vated by TNF and play an important role in TNF-medi-
TRAF1/ mice have increased sensitivity to TNF- ated cell activation. Activation of the NF-B pathway in
induced skin necrosis and suggest that TRAF1 normally response to TNF was enhanced in TRAF1/ T cells as
inhibits the cytotoxic effects of TNF on skin. evidenced by increased IKK activity, enhanced NF-B
nuclear translocation, and increased expression of
Discussion NF-B-regulated genes (Figures 6A–6C). Moreover,
TRAF1/ T cells had enhanced SAPK/JNK phosphory-
In this study we demonstrate that T cells from TRAF1/ lation and enhanced nuclear AP-1 binding activity in
mice exhibit enhanced proliferation to anti-CD3 mAb response to TNF. These findings suggest that TRAF1 is a
and that activated TRAF1/ T cells are hyperresponsive negative regulator of TNFR2 signaling in T cells, whereas
to TNF. Furthermore, skin from TRAF1/ mice is hyper- data with TRAF1/B cells (Figure 2) suggest that TRAF1
sensitive to TNF-induced skin necrosis. These findings is not important in regulating NF-B and AP-1 activation
suggest that TRAF1 is a negative regulator of TNF ac- by CD40.
tivity. One possible mechanism of TRAF1 inhibition of TNF
TRAF1/ mice are born normal and do not develop signaling is that TRAF1 competes with TRAF2 for bind-
ing to TNFR2. To date, attempts to immunoprecipitateany visible problems with age, which is consistent with
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Figure 7. TNF-Induced Skin Necrosis Is Ex-
aggerated in TRAF1-Deficient Mice
(A) Skin necrosis in WT, RAG-2/, and
TRAF1/ mice after subcutaneous injections
of TNF 3 g/day and 1.5 g/day for 5 consec-
utive days.
(B) Histological examination of the skin from
uninjected and TNF injected (as in [A]) WT
and TRAF1/ mice, fixed and stained with
hematoxylin and eosin.
TRAF2 with TNFR2 from activated primary T cells have Takahashi et al., 1999). However, examination of periph-
eral T cell clonal expansion and deletion following TCRnot been successful. Another possibility is that TRAF1
forms an inactive heterodimer by binding to TRAF2. A signaling after injection of the superantigen SEB re-
vealed no differences between TRAF1/ and WT micethird possibility is that TRAF1 may regulate molecules
other than TRAF2 that are needed for efficient TRAF2 (Figure 4). Because both Fas/CD95 and TNF have been
implicated in clonal deletion of mature T cells followingsignaling, and a fourth possibility is that TRAF1 may
recruit other molecules that negatively regulate TNF sig- T cell receptor engagement (Miethke et al., 1996; Mixter
et al., 1994; Papiernik et al., 1995; Singer and Abbas,naling, such as A20 (Lee et al., 2000; Song et al., 1996).
Further work is needed to understand the precise bio- 1994; Sytwu et al., 1996), it will be of interest to examine
superantigen-induced apoptosis of mature T cells inchemical basis of the inhibition of TNFR2 signaling by
TRAF1 and of the role of TRAF1 in the regulation of TRAF1/ mice bred on the lpr background to determine
if TRAF1 plays a role in TNF-mediated cell death.signaling by other TNFR family members.
OX40 and 4-1BB have been reported to be important We used a model of TNF-induced skin necrosis to
examine the effect of TRAF1 deficiency on TNF signalingin the peripheral T cell expansion (Maxwell et al., 2000;
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C-terminal peptide of the murine TRAF1 (Santa Cruz) overnight atin vivo. We found that RAG-2/ mice, which lack T
room temperature, then with goat anti-rabbit polyclonal antibodiesand B cells (Shinkai et al., 1992), are resistant to TNF-
conjugated with peroxidase (Pierce) for 4 hr at room temperature.mediated skin necrosis, suggesting that lymphocytes
Bound conjugates were detected by ECL Super-Signal-Dura kit
play an important role in this in vivo effect of TNF. (Pierce).
TRAF1/ mice were found more susceptible to TNF-
induced skin necrosis than WT mice (Figure 7). This Proliferation of B and T Cells
Single-cell suspensions from spleen, bone marrow, thymus, andsuggests that TRAF1 normally protects skin from lym-
lymph nodes were isolated on a density gradient of Lympholyte-Mphocyte-mediated TNF-induced necrosis. It is tempting
(Accurate). B cells were prepared by depletion of T cells from single-to speculate that the hypersensitivity of T cells to TNF
spleen-cell suspension. Splenocytes were incubated with mAbs to
may underlie the increased skin sensitivity to TNF in CD4, CD8, and Thy1.1 (1 g/ml each), washed twice with PBS, and
TRAF1/ mice. However, because TRAF1, in addition incubated with magnetic Dynabeads M-450 conjugated with sheep
anti-rat IgG (Dynal). Purified B cells were cultured at 1  105/well forto T cells, is expressed in the skin (Zapata et al., 2000),
72 hr and activated by F(ab)2 fragments of goat anti-IgM polyclonalwe cannot at present rule out increased sensitivity of
antibodies (Rockland) and/or anti-CD40 mAb HM40-3 (PharMingen)TRAF1/ skin cells to cytotoxic damage.
at the indicated concentrations. T cells were prepared by depletionThe results of the present study suggest that TRAF1
of B cells from single-spleen-cell suspension. Splenocytes were
is a negative regulator of TNF signaling through TNFR2. incubated with rat mAbs to CD19, CD21, and IgM (1 g/ml each)
Induction of TRAF1 may trigger a feedback regulatory for 30 min, washed twice with PBS, and incubated with magnetic
Dynabeads M-450 conjugated with sheep anti-rat IgG. Purified Tloop that downregulates signals delivered by TNF. This
cells (95% CD3 cells) were activated by anti-CD3 mAb 145-2C11is very important, given the critical role TNF plays in
(BD Pharmingen) by culturing at 1  105/well for 72 hr. Anti-CD3infection, immunity, and cancer.
mAb in PBS was absorbed at the indicated concentrations onto
plastic wells for 24 hr before addition of T cells. For costimulation,
Experimental Procedures
anti-CD28 mAb 37.51 (BD Pharmingen) was absorbed on plastic
together with anti-CD3 mAb (0.1 g/ml). Recombinant murine TNF
Generation of TRAF1-Deficient Mice
and IL-2 (R&D) were used at the indicated concentrations. Prolifera-
Recently, we cloned and characterized the murine TRAF1 gene iso-
tion was assessed by the incorporation of [3H]-thymidine added
lated from a Lambda FIXII library (Stratagene) (Dunn et al., 1999).
(1 Ci/well) during the last 6 hr of culture. For proliferation with TNF,
The targeting construct was assembled using the pPNT vector,
anti-CD3-activated T cells were collected after 3 days incubation,
kindly provided by Dr. Richard Mulligan (Children’s Hospital, Boston
and live cells were isolated on a density gradient of Lympholyte-M
MA). The 6.5 kb XbaI/XbaI fragment and the 4.5 kb HindIII/HindIII
and activated with indicated concentrations of TNF at 2  104 cells/
fragment of the TRAF1 gene were used as a 5 arm and a 3 arm,
well for 72 hr. Anti-TNFR1 mAb 55R170 and anti-TNFR2 mAb TR75-
respectively (Figure 1A). In the final construct, the direction of neo
54 were purchased from BD Pharmingen.
gene transcription was opposite to that of TRAF1 gene transcription.
The construct (20 g) was linearized by digestion at the unique NotI
Electrophoretic Mobility Shift Assay
site in pPNT and used to transfect 2  107 embryonic stem cells
Spleen cells at 106/ml were either left unstimulated or were stimu-
(J1) obtained from Dr. R. Jaenisch (MIT, Cambridge, MA). ES cells
lated with anti-CD40 antibodies (1g/ml) for 1 hr. Anti-CD3 activated
were selected by growing them in medium containing 0.4 mg/ml
T cells were left unstimulated, stimulated with TNF (100 ng/ml), or
G418 and 10 g/ml gancyclovir. ES clones were identified by South-
stimulated with PMA (20 ng/ml) for 30 min. Cells (3  106) were
ern blotting for the presence of homologous recombination. Geno-
washed twice with ice-cold PBS, resuspended in ice-cold 10 mM
mic DNA was isolated, digested with EcoRI, and resolved in 1%
Hepes buffer (pH 7.9) containing 1.5 mM MgCl2, 10 mM KCl, 0.5 mMagarose gel. Southern blots were hybridized with the 3 probe (probe
DTT, and EDTA-free CPI, and incubated for 10 min on ice. Nuclei
A in Figure 1A). The targeted ES clone was injected into 3.5-day-
were pelleted for 2 min at 5000 rpm at 4C and resuspended in ice-
old C57BL/6 blastocysts, which were then transferred into Swiss cold 20 mM Hepes buffer (pH 7.9) containing 25% glycerol, 420 mM
foster mothers. Resulting chimeric males were crossed with C57BL/ NaCl, 1.5 mM MgCl2, 0.5 mM EDTA, 0.5 mM DTT, and CPI cocktail.6 females. Tail DNAs of agouti offspring were analyzed by Southern Oligonucleotides used in these experiments are as follows: NF-B
blotting. TRAF1 heterozygous (/) mice from the F1 generation sequence of human imunodefficiency virus (HIV) 1 Long terminal
were used to obtain TRAF1 homozygous (/) mice by brother- Repeat TCGCTGGGGACTTTCCAGGGA (Nabel and Baltimore,
sister mating. To identify homozygous TRAF1 KO mice, F2 offspring 1987); consensus AP-1 sequence, CGCTTGATGAGTCAGCCG (Pro-
from these crosses were genotyped by Southern blotting and PCR mega). For each reaction, 2  104 cpm (0.1 ng) of radiolabeled
of tail DNA. PCR analysis was performed with two different primer oligonucleotide probe was incubated with 2 g of nuclear extract
sets. The MTWT1 (GAGGCTCAGACATATTGAAGA) and MTWT2 in 20 l of binding buffer (10 mM Tris-HCl [pH 7.5], 50 mM NaCl,
(ACCAAATTGAAACTCGTTTTGATC) set was used to amplify a 1.4 5% glycerol, 50 ng/ml poly [dI-dC], 0.1% NP-40, 1 mM DTT, and
kb fragment from the WT allele. The MTEOG (GCCCAATGCGAGCA CPI). Samples were run on 5% PAGE in 1 TBE.
GAAG) and NeoS (CGACCACCAAGC GAAACAT) set was used to
amplify a 1.2 kb fragment from the KO TRAF1 allele. PCR was Flow Cytometry Analysis
performed with Taq polymerase (Roche) in 1 PCR buffer with 4% FACS analysis was performed on thymi from 3-week-old mice and
DMSO, 0.4 mM dNTPs, and 0.5 M of each primer. After the hot on lymph nodes and spleens cells from 6- to 12-week-old mice.
start (2 min at 94C), samples were amplified for 35 cycles: 30 s at Lymphoid organs were teased by glass slides, and live cells were
94C, 30 s at 53.5C, and 2 min at 72C. isolated on a density gradient of Lympholyte-M and stained with
appropriate antibodies in 2% rat serum PBS containing Fc-block,
Western Blotting fixed in 2% formaldehyde, and analyzed on a FACSCalibur cytom-
Splenocytes (50 106) from WT and TRAF1/ mice were stimulated eter (BD Pharmingen). FITC- and PE-labeled antibodies were pur-
overnight with anti-CD40 antibody HM40-3 purchased from BD Phar- chased from Pharmingen. Anti-CD8 and anti-B220 (RA3-6B2) anti-
mingen. Cells were washed twice in ice-cold PBS, then lysed in bodies labeled with QuantumRed were purchased from Sigma. For
buffer containig 10 mM Hepes, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM CD25, intracellular IL-2 and Annexin.V detection purified T cells were
DTT, and 1 Complete Protease Inhibitor (CPI) cocktail (Roche). activated by anti-CD3 mAb 145-2C11 for 16 hr and stained according
The cell equivalent of 5  106 splenocytes was resolved on 10% to BD Pharmingen recommendations.
SDS-PAGE minigel (BioRad), transferred to nitrocellulose membrane
(Gelman), and incubated with blocking solution (0.2% gelatin, 2% Antibody Responses
BSA, 0.1% Tween 20 in PBS) for 4 hr at room temperature. Mem- To determine the antibody response to the T-dependent antigen
ovalbumin, 10- to 12-week-old mice were immunized intraperitone-branes were incubated with rabbit polyclonal antibody S-19 against
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ally with 20 g of ovalbumin precipitated with alum and boosted Carpentier, I., and Beyaert, R. (1999). TRAF1 is a TNF inducible
regulator of NF-kappaB activation. FEBS Lett. 460, 246–250.the same way at day 21 and bled at days 0, 7, 14, 21, 28, and
35. The magnitude of the anti-ovalbumin antibody response was Cope, A.P., Aderka, D., Wallach, D., Kahan, M., Chu, N.R., Brennan,
detected by ELISA as previously described (Spergel et al., 1998). F.M., and Feldmann, M. (1995). Soluble TNF receptor production by
Briefly, anti-isotype specific mAbs at a concentration 2 g/ml in activated T lymphocytes: differential effects of acute and chronic
PBS were absorbed to 96-well plates (NuncMaxisorb) for 16 hr at exposure to TNF. Immunology 84, 21–30.
4C. For IgG1, IgG2a, and IgE isotype determination, sera were
Dunn, I.F., Geha, R.S., and Tsitsikov, E.N. (1999). Structure of the
diluted 1/1000, 1/50, and 1/25, respectively, and added to the wells
murine TRAF1 gene. Mol. Immunol. 36, 611–617.
for 1 hr at 37C. Biotinylated-ovalbumin was incubated for 4 hr at
Erickson, S.L., de Sauvage, F.J., Kikly, K., Carver-Moore, K., Pitts-37C. Bound ovalbumin was revealed with the strepavidin-peroxi-
Meek, S., Gillett, N., Sheehan, K.C., Schreiber, R.D., Goeddel, D.V.,dase conjugate (BD Pharmingen) according to the manufacturer’s
and Moore, M.W. (1994). Decreased sensitivity to tumour-necrosisrecommendations. For T-independent antigens, mice were immu-
factor but normal T-cell development in TNF receptor-2-deficientnized intraperitoneally with 10 g LPS-TNP (Sigma) in PBS or with
mice. Nature 372, 560–563.10 g TNP-Ficoll (a gift of Dr. F.D. Finkelman, Bethesda, MD) at day
Gramaglia, I., Cooper, D., Miner, K.T., Kwon, B.S., and Croft, M.0 and bled at days 0, 7, 14, 21, and 28. Levels of antigen-specific
(2000). Co-stimulation of antigen-specific CD4 T cells by 4–1BBantibody responses were analyzed by TNP-specific ELISA using 96-
ligand. Eur. J. Immunol. 30, 392–402.well plates coated with 10 g/ml TNP-conjugated BSA in PBS.
Gramaglia, I., Weinberg, A.D., Lemon, M., and Croft, M. (1998). Ox-
Clonal Deletion and Expansion of Peripheral T Cells 40 ligand: a potent costimulatory molecule for sustaining primary
For clonal deletion experiments, two inguinal and two auxiliary CD4 T cell responses. J. Immunol. 161, 6510–6517.
lymph nodes were teased by glass slides, and debris was separated
Hendriks, J., Gravestein, L.A., Tesselaar, K., van Lier, R.A.W., Schu-
using a cell strainer (Falcon). Cells were washed twice with ice-cold
macher, T.N.M., and Borst, J. (2000). CD27 is required for generation
1% FCS PBS and stained with appropriate antibodies. 5-Bromo-
and long-term maintenance of T cell immunity. Nat. Immunol. 1,
2-deoxiuridine (BrdU) labeling for in vivo proliferation studies was
433–440.
performed as previously described (Sadlack et al., 1994), with some
Hintzen, R.Q., Lens, S.M., Lammers, K., Kuiper, H., Beckmann, M.P.,modifications. Mice were injected i.p. with 1 ml of BrdU in PBS (1
and van Lier, R.A. (1995). Engagement of CD27 with its ligand CD70mg/ml) at 16 hr before death. Cells (n  5  105) were stained
provides a second signal for T cell activation. J. Immunol. 154,with anti-CD4-FITC or anti-CD8-FITC mAbs in the ice-cold PBS/Rat
2612–2623.serum/Fc-Block. Cells were washed with PBS, resuspended in 50
Horie, R., and Watanabe, T. (1998). CD30: expression and functionl of PBS, and injected into 1 ml of 70% ice-cold ethanol. After
in health and disease. Semin. Immunol. 10, 457–470.incubation for 15 min on ice, cells were spun down and resupended
in 0.5 ml of 1 N HCl/0.5% Tween-20 for 20 min at 37C. The cells Hurtado, J.C., Kim, S.H., Pollok, K.E., Lee, Z.H., and Kwon, B.S.
were spun down and incubated for 5 min in 0.1 M sodium borate (1995). Potential role of 4–1BB in T cell activation. Comparison with
buffer (pH 8.5). After washing twice with PBS, cells were stained the costimulatory molecule CD28. J. Immunol. 155, 3360–3367.
with anti-BrdU-PE for 30 min in PBS/1% FCS/0.5% Tween-20. Hurtado, J.C., Kim, Y.J., and Kwon, B.S. (1997). Signals through
4–1BB are costimulatory to previously activated splenic T cells and
TNF-Mediated Skin Necrosis inhibit activation-induced cell death. J. Immunol. 158, 2600–2609.
Two- to four-month-old WT and TRAF1/ mice were shaved in
Irmler, M., Steiner, V., Ruegg, C., Wajant, H., and Tschopp, J. (2000).the lower back area and subcutaneously injected with indicated
Caspase-induced inactivation of the anti-apoptotic TRAF1 duringamounts of recombinant murine TNF (R&D) in 150 l of 0.9% saline
Fas ligand-mediated apoptosis. FEBS Lett. 468, 129–133.for 5 consecutive days. On day 6 after injection, lesion formation
Jang, I.K., Lee, Z.H., Kim, Y.J., Kim, S.H., and Kwon, B.S. (1998).was recorded photographically, and biopsies were taken and fixed
Human 4–1BB (CD137) signals are mediated by TRAF2 and activatein 2% paraformaldehyde. Sections were made and stained with
nuclear factor-kappa B. Biochem. Biophys. Res. Commun. 242,hematoxylin-eosin.
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